Today, Atomo Diagnostics and Access Bio Inc. jointly announced a strategic partnership to leverage the respective strengths of both companies and expand point of care HIV testing in global markets.
Atomo will supply its award-winning AtomoRapid™ lateral flow diagnostic test platforms for use with Access Bio’s in vitro HIV rapid test. The product will be commercialised by Access Bio in professional use markets under its CareStart™ brand in territories across Africa, South East Asia, South America and CIS countries – where, according to the World Health Organisation, demand for HIV RDTs will reach more than 400 million tests per year by 2020.
Atomo’s CEO John Kelly summarises what this means for the company: “We are excited about this commercial partnership with Access Bio, a recognised market leader in rapid diagnostic testing. Our AtomoRapid™platforms are proving their excellent usability and performance for a range of applications internationally, and this new partnership adds significantly to our long-term growth plans. Moreover, it demonstrates our continued commitment to tackling HIV by enabling greater access to best-in-class diagnostics in areas hardest hit by the disease.”